Healthcare provider profile · identity verified

Ton That Chieu, MD

General Practice · TAKOMA PARK, MD · NPI 1215039391

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	585	199
Atorvastatin Calcium	Atorvastatin Calcium	563	194
Metformin Hcl	Metformin Hcl	336	115
Losartan Potassium	Losartan Potassium	280	97
Metoprolol Succinate	Metoprolol Succinate	214	81
Famotidine	Famotidine	177	74
Lisinopril	Lisinopril	147	55
Lovastatin	Lovastatin	144	51
Tamsulosin Hcl	Tamsulosin Hcl	127	49
Hydrochlorothiazide	Hydrochlorothiazide	119	41
Glipizide Er	Glipizide	114	39
Pantoprazole Sodium	Pantoprazole Sodium	90	46
Gabapentin	Gabapentin	80	31
Rosuvastatin Calcium	Rosuvastatin Calcium	80	33
Fluticasone Propionate	Fluticasone Propionate	71	36
Glimepiride	Glimepiride	69	23
Allopurinol	Allopurinol	68	25
Triamcinolone Acetonide	Triamcinolone Acetonide	67	49
Omeprazole	Omeprazole	57	31
Simvastatin	Simvastatin	57	18
Alendronate Sodium	Alendronate Sodium	55	16
Albuterol Sulfate Hfa	Albuterol Sulfate	54	19
Levothyroxine Sodium	Levothyroxine Sodium	52	19
Clopidogrel	Clopidogrel Bisulfate	49	20
Metoprolol Tartrate	Metoprolol Tartrate	47	18
Jardiance	Empagliflozin	44	16
Meclizine Hcl	Meclizine Hcl	44	27
Diclofenac Sodium	Diclofenac Sodium	43	18
Naproxen	Naproxen	43	26
Tradjenta	Linagliptin	43	14
Furosemide	Furosemide	41	16
Donepezil Hcl	Donepezil Hcl	40	12
Cromolyn Sodium	Cromolyn Sodium	37	16
Valsartan	Valsartan	35	11
Felodipine Er	Felodipine	32	12
Eliquis	Apixaban	29	11
Fluocinonide	Fluocinonide	29	14
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Finasteride	Finasteride	28	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Loperamide	Loperamide Hcl	26	21
Montelukast Sodium	Montelukast Sodium	26	suppressed
Cyclosporine	Cyclosporine	25	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	23
Carvedilol	Carvedilol	23	suppressed
Atenolol	Atenolol	22	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	21	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	19	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	18	suppressed
Cephalexin	Cephalexin	18	16
Prednisone	Prednisone	18	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Trazodone Hcl	Trazodone Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Risperidone	Risperidone	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Entecavir	Entecavir	12	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error